Finally, anticancer drugs may directly or indirectly activate platelets [44].Cancer patients undergoing systemic treatment for their malignancy are among the highest risk populations for thromboembolic complications; highly thrombogenic chemotherapy agents (HTAs) include platinum compounds, 5-FU, capecitabine, gemcitabine, hormonal therapy, anti-angiogenesis treatment, e.g., bevacizumab, and supportive treatment, e.g., corticosteroids, erythropoietin [45]. This evidence concerns the gene EPO and cancer.